Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
every 3 months
No
Jalid Sehouli
Principal Investigator
Charité Campus Virchow Klinikum
Germany: Federal Institute for Drugs and Medical Devices
3002000
NCT00158379
July 2003
June 2008
Name | Location |
---|